Amgen is buying into Novartis' early-stage BACE program for Alzheimer's, paying an unspecified upfront and milestones in exchange for a cut of the program, which looks to slash the production of a key toxic protein widely viewed as a prime suspect in the development of the memory-wasting ailment.
Sanofi is backing out of a collaboration with Ardelyx that could have paid out nearly $200 million, returning a handful of candidate treatments for high phosphates in patients with kidney disease.
Digital health startup DynoSense is teaming up with a Chinese health services company to bring its patient monitoring technology to China, expanding its global reach weeks after the company reeled in new funds to fuel stateside approval for its device.
Three months after Amgen washed its hands of the psoriasis drug brodalumab, its development partner AstraZeneca has found the exit door as well. The pharma giant auctioned off the Phase III-complete therapy to the wheeler dealers at Valeant in exchange for $100 million upfront, $170 million in prelaunch milestones and another $175 million in sales bonuses.
Sanofi is lending its weight to Google's ambitions in life sciences, joining the tech giant's recently unleashed healthcare division in hopes of developing new technologies to help manage diabetes.
Google is teaming up with French drugmaker Sanofi for a diabetes monitoring collaboration, furthering the tech giant's foray into medical devices and its commitment to developing innovative products for the disease.
A key drug company in China fired a new salvo in the online over-the-counter healthcare market with an eye on wider sales of ethical products in hopes the China Food and Drug Administration (CFDA) will come through on plans to allow online sales of prescription drugs at some point this year.
The U.S. Department of Defense is sinking funds into a Silicon Valley initiative aimed at creating "flexible" electronics, furthering the agency's commitment to investing in innovative devices that could help soldiers on the battlefield.
Johnson & Johnson is joining forces with hardware manufacturing company PCH to launch a consumer-health focused hardware startup incubator, building on J&J's commitment to investing in early-stage companies to spur med tech innovation.
In an effort to widen the reach of its flu vaccines business--and to develop new vaccines on a familiar platform--Takeda has inked an agreement to expand its rights to the Vero cell technology platform for vaccines production from Florida's Nanotherapeutics, Inc.